Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
HUTCHMED (China) ( (HK:0013) ) has shared an update.
HUTCHMED (China) Limited has appointed Deutsche Bank AG, trading as Deutsche Numis, as its joint Corporate Broker in London, replacing HSBC Bank plc. Panmure Liberum Limited and Cavendish Capital Markets Limited will continue their roles as joint Corporate Brokers, with Panmure Liberum also acting as Nominated Advisor in London. This strategic move may enhance HUTCHMED’s financial operations and strengthen its market presence in London.
More about HUTCHMED (China)
HUTCHMED (China) Limited is an innovative, commercial-stage biopharmaceutical company focused on the discovery, global development, and commercialization of targeted therapies and immunotherapies for cancer and immunological diseases. The company has successfully marketed its first three medicines in China, with one also approved in the US, Europe, and Japan.
For an in-depth examination of 0013 stock, go to TipRanks’ Overview page.